Wait, what happened?

In a shocking turn of events, we are finally studying the female body. (EVERYBODY SAY “WHOOP WHOOP!”) On May 12, 2026, Polycystic Ovary Syndrome – more commonly referred to as PCOS – was renamed Polyendocrine Metabolic Syndrome (PMOS) to more accurately reflect the nature of the condition.

PMO-what?

PMOS refers to a set of symptoms, including but not limited to: irregular periods; high levels or high activity of androgens; polycystic ovaries; abnormal hair growth; and infertility. These symptoms are associated with a highly complex interaction of many parts of the endocrine system in people with a female reproductive system that affects roughly 1 in 8 women. Polycystic ovaries are only one symptom in a laundry list of issues that people with this disease face, but it was a relatively easy symptom to identify and, thus, it took precedence in defining the disease during the early stages of understanding it and its effects on patients.

And the name matters so much BEcause…?

The name of a disease is integral to the diagnosis and treatment of the disease, as well as in giving the patient closure in defining the source of their medical problems. The name of a disease is the first thing someone knows about it. It is that disease’s trademark. In many cases, it defines the disease. In others, it honors the people who suffered from it or the person who discovered it. The name of a disease is important simply because it groups a list of symptoms together and connects them to one common source. The previous name put an emphasis on the ovaries, which led to many missed diagnoses because doctors would mainly look at the ovaries instead of the bigger picture and considering that the patient’s symptoms may all be connected to one disease. The emphasis on the ovaries also led to the research being done on PMOS, which was already few and far between, focusing on the ovaries and not the interactions of multiple hormones and hormone secreting glands. This led to poorly informed research findings. The findings were technically accurate, but many of them were missing certain pieces and various aspects of the disease, such as male-pattern baldness, went unnoticed and underresearched for way too long. The medical system has consistently failed patients with female reproductive systems for far too long and this is one of many needed steps in the right direction towards providing better care.

But Why change the name now?

Polycystic ovaries are not the most commonly reported symptom of the disease by patients, so it made sense to decentralize the ovaries from the disease by changing the name. The new name Polyendocrine Metabolic Syndrome also gives a better, more all encompassing name for the disease, rather than focusing on one part of the disease. Many doctors also felt that the specificity of the former name was a handicap on furthering our understanding of the disease. Because, as previously mentioned, PMOS does not just affect the ovaries and the reproductive system. It is a comprehensive disease including multiple different hormone interactions that stem from many different areas of the body. PMOS has widespread physical symptoms and vast effects on the mental health of those affected by it. 

Women affected by the disease have been the primary advocates for changing the name, and it has been a long time coming. Thanks to patient advocates, doctors, and the specialists who finally listened, the name of the disease is now Polyendocrine Metabolic Syndrome which better reflects its widespread effect on the body, and will hopefully lead to better research on the disease and better care for patients affected by it.